BioSpace News Archive

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate in the following investor conferences in September

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta’s management team has been invited to participate at H.C. Wainwright 21st Annual Global Investment Conference in New York, NY.

Harmonic Bionics, Inc. announced today that Christopher Prentice has been appointed Chief Executive Officer and member of the Harmonic Bionics Board of Directors effective immediately.

IRLAB announced that the in-depth analysis of the data from the recently concluded Phase IIa study of IRL790 in Parkinson’s patients with L-dopa induced dyskinesia brings further evidence of the drug candidate’s ability to significantly and meaningfully improve daytime movement quality.

OKYO Pharma Limited is pleased to announce potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of DED in mice.

GB Sciences, Inc. announced the appointment to GB Sciences’ executive team of Darin Carpenter as the company’s new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.

The National Council of State Boards of Nursing, www.ncsbn.org, inducted its 13th group of Fellows of the NCSBN Institute of Regulatory Excellence during the NCSBN Annual Meeting and Delegate Assembly, held in Chicago, Aug. 21-23, 2019.

Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, announced that management will present a company overview at the following investor conferences

Final topline results remain on target for first half 2020

Cardiovascular Systems, Inc. announced that management will participate and host investor meetings at the following three conferences